Reports
Sale
Global Antihyperlipidemic Drugs Market Size, Growth, Report: By Drug Class: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination; By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Drug Stores, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Antihyperlipidemic Drugs Market Outlook
The global antihyperlipidemic drugs market size was valued at USD 12.91 billion in 2023, driven by the increasing prevalence of coronary heart diseases, lipid disorders and hyperlipidaemia cases globally. The market is expected to grow at a CAGR of 5.8% during the forecast period of 2024-2032, with the values likely to rise from USD 13.66 billion in 2024 to USD 21.44 billion by 2032.
Antihyperlipidemic Drugs: Introduction
Antihyperlipidemic drugs, also known as hypolipidemic drugs, are agents used to lower the lipoprotein (fats, cholesterol, triglyceride) levels in the blood. Cholesterol is a fat-like, waxy substance present in the blood. It is crucial to the healthy functioning of the body as it is used in building healthy cells, vitamins, and other hormones. However, too much cholesterol gets accumulated on the blood vessels and can lead to serious cardiac issues, including heart failure and stroke.
Lifestyle changes like a healthier diet, regular exercise, minimal consumption of alcohol can prevent or treat unhealthy cholesterol levels for some people. However, people with severely high cholesterol levels need antihyperlipidemic drugs for treatment.
Global Antihyperlipidemic Drugs Market Analysis
Hyperlipidaemia is a critical medical condition, arising due to abnormally high levels of cholesterol in the body. Around 24% of the cardiovascular diseases are attributable to high LDL cholesterol in the body. It occurs due to accumulation of atherosclerotic plaque resulting in insufficient blood flow to important body parts like brain, heart, and limbs. As a result, significant antihyperlipidemic drugs market growth can be anticipated in the coming years.
Statins are the most preferred treatment alternative for lowering LDL (bad) cholesterol and triglycerides while increasing HDL (good) cholesterol in the body. However, it also poses a risk of symptoms like headaches, dizziness, or digestive issues. Although the side effects are commonly treated with the help of combination medicines, there has been significant research to come up with improved and side-effect free statins. For instance, atorvastatin nanocrystals have been developed to combat the issue of its poor gastric solubility and low absolute bioavailability. This indicates that we can expect a significant growth in antihyperlipidemic drugs market value with rising research and development in the field.
Medical researchers are adopting new technologies to develop potent and affordable antihyperlipidemic drugs, with an aim to curb the threat of chronic cardiovascular diseases majorly associated with cholesterol levels. Bempedoic acid works on the mechanism of cholesterol synthesis inhibition. Other emerging drugs are Evinacumab (based on the use of monoclonal antibodies), Inclisiran and Volanesorsen (based on antisense oligonucleotides mechanism). Such developments in the pharmaceutical industry will be a key factor for high market demand in the future.
Global Antihyperlipidemic Drugs Market Segmentation
Market Breakup by Drug Class
- Statins
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- Combination
Market Breakup by Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Drug Stores
- E-Commerce
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Antihyperlipidemic Drugs Market Overview
Majority of the global antihyperlipidemic drugs market share has been owned by the North American region. This is due to the high number of cardiovascular diseases in the region. However, with a robust healthcare industry that holds a prominent infrastructure for diagnostics and increased awareness around cardiac health, the cases have decreased in the area. It has been observed that cardiovascular mortality rates have decreased in high-income western countries like north-western Europe, North America, and Australia , inverse to the rise in Asia.
Nowadays, majority of the deaths attributable to high LDL cholesterol are recorded in east, southeast, and south Asia, which indicates that global market for antihyperlipidemic drugs will observe a surge in the territory. Asian countries are home world’s maximum percentage of geriatric population. Hence, they are already prone to face a significant hike in the number of cardiac surgeries. Moreover, rising investments around developing a proficient pharmaceutical and healthcare industry by the governments will fuel market growth.
Global Antihyperlipidemic Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bristol-Myers Squibb Company
- Merck & Co.
- AstraZeneca
- Mylan N.V
- Abbott
- Aparito Ltd.
- Amgen Inc.
- Daiichi Sankyo Company
- Pfizer Inc.
- Dr. Reddy’s Laboratories Ltd
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Antihyperlipidemic Drugs Market Overview
3.1 Global Antihyperlipidemic Drugs Market Historical Value (2017-2023)
3.2 Global Antihyperlipidemic Drugs Market Forecast Value (2024-2032)
4 Global Antihyperlipidemic Drugs Market Landscape
4.1 Global Antihyperlipidemic Drugs: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Antihyperlipidemic Drugs: Product Landscape
4.2.1 Analysis by Distribution Channel
4.2.2 Analysis by Drug Class
4.2.3 Analysis by Region
5 Global Antihyperlipidemic Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Antihyperlipidemic Drugs Market Segmentation
6.1 Global Antihyperlipidemic Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Statins
6.1.3 PCSK9 Inhibitors
6.1.4 Bile Acid Sequestrants
6.1.5 Cholesterol Absorption Inhibitors
6.1.6 Fibric Acid Derivatives
6.1.7 Combination
6.2 Global Antihyperlipidemic Drugs Market by Distribution Channel
6.2.1 Market Overview
6.2.2 Hospitals Pharmacies
6.2.3 Retail Pharmacies
6.2.4 Drug Stores
6.2.5 E-Commerce
6.3 Global Antihyperlipidemic Drugs Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Global Antihyperlipidemic Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Global Antihyperlipidemic Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Global Antihyperlipidemic Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Global Antihyperlipidemic Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Global Antihyperlipidemic Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Bristol-Myers Squibb Company
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Merck & Co.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 AstraZeneca
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Mylan N.V
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Abbott
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Aparito Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Amgen Inc.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Daiichi Sankyo Company
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Pfizer Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Dr. Reddy’s Laboratories Ltd
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 12.91 billion in 2023, driven by the increasing prevalence of cardiac diseases, lipid disorders, and hyperlipidaemia cases globally.
The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032, likely to reach a market value of USD 21.44 billion by 2032.
The emphasis on reducing the number of deaths associated with high cholesterol, along with new drug developments, drive the demand for these drugs.
High income countries like the United States, north-western Europe, Australia have seen a decrease in number of cardiac deaths. This can be attributed to the existence of a profound healthcare and pharmaceutical industry. However, the fastest growth can be expected in Asian region, owing to a high percentage of aging population and increased investments by the government to improve healthcare industry.
Antihyperlipidemic drugs include statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination.
What are the major global regional market for antihyperlipidemic drugs, according to the EMR report?
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
The distribution channels in the market are hospitals pharmacies, retail pharmacies, drug stores and E-commerce.
Key players involved in the market are Bristol-Myers Squibb Company, Merck & Co., AstraZeneca, Mylan N.V, Abbott, Aparito Ltd., Amgen Inc., Daiichi Sankyo Company, Pfizer Inc., and Dr. Reddy’s Laboratories Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER